RecruitingPhase 1NCT07813637

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer

Sponsor

Janux Therapeutics

Enrollment

110 participants

Start Date

Sep 10, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Metastatic Prostate Cancer Castration-Resistant Prostate Cancer (CRPC)Metastatic Castration-Resistant Prostate Cancer Patients

Summary

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JANX007, a drug called JANX007, and others for people with castration-resistant prostate cancer (crpc), metastatic castration-resistant prostate cancer patients, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.